This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
by Zacks Equity Research
uniQure (QURE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance
by Zacks Equity Research
The FDA decision on Pfizer's (PFE) BLA for marstacimab for hemophilia A and B is expected in the fourth quarter of 2024, while the European Commission's decision is expected in 2025.
Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for uniQure (QURE) points to a 405.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -26.17% and 57.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
uniQure (QURE) Up on Restructuring Plans, Workforce Reduction
by Zacks Equity Research
uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.
UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing
by Zacks Equity Research
A final decision on Pfizer's (PFE) BLA filing, seeking approval for hemophilia B gene therapy, treatment is expected by second-quarter 2024.
uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
by Zacks Equity Research
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.
Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in UniQure (QURE) Stock?
by Zacks Equity Research
Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.
UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal
by Zacks Equity Research
Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
by Zacks Equity Research
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 8.11% and 86.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate uniQure (QURE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?
by Zacks Equity Research
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.